OptiNose (OPTN) to Release Earnings on Thursday

OptiNose (NASDAQ:OPTN) is expected to be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect OptiNose to post earnings of ($0.67) per share and revenue of $21.02 million for the quarter.

OptiNose Trading Down 9.3 %

Shares of OptiNose stock opened at $5.27 on Tuesday. The company’s 50-day moving average price is $5.96 and its two-hundred day moving average price is $8.93. OptiNose has a 52 week low of $4.82 and a 52 week high of $31.50. The stock has a market cap of $53.02 million, a PE ratio of -1.26 and a beta of -0.17.

Wall Street Analysts Forecast Growth

Several brokerages have commented on OPTN. Lake Street Capital dropped their price target on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. HC Wainwright boosted their price target on shares of OptiNose from $5.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. Finally, Piper Sandler dropped their price target on OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.